Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis Healing:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or IV twice daily. Doses may be increased as needed. Doses up to 240 mg IV daily have been used.
## Pediatric Dosing
* **Erosive Esophagitis Healing (5 to 16 years):** 20 mg orally once daily for up to 8 weeks. Higher doses (40 mg once daily) may be considered.
* **Erosive Esophagitis Healing (1 to <5 years):** 1.2 mg/kg/day orally once daily, not to exceed 40 mg/day, for up to 8 weeks.
Dosing in neonates and infants for GERD symptoms is not FDA-approved. Use is based on extrapolation and expert consensus, and may vary significantly by institution.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Diarrhea, headache, abdominal pain, nausea, dizziness, fatigue.
Serious: *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (can be asymptomatic or symptomatic), vitamin B12 deficiency.
## Key Drug Interactions
* **Certain Antiretrovirals (e.g., rilpivirine, atazanavir):** Decreased absorption due to increased gastric pH.
* **Methotrexate:** May increase methotrexate levels.
* **CYP2C19 Substrates (e.g., clopidogrel):** Potential for reduced efficacy of clopidogrel if pantoprazole is taken concurrently, though clinical significance is debated.
## Monitoring
* Monitor for signs and symptoms of *C. difficile* infection.
* Consider monitoring magnesium levels with long-term PPI use, especially if concomitant use of other drugs known to cause hypomagnesemia (e.g., diuretics).
* Assess for bone pain or risk factors for fractures.
* Monitor for symptoms of B12 deficiency with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* Intravenous administration requires reconstitution and further dilution. Refer to specific institutional guidelines for IV preparation and administration.
* Long-term PPI use has been associated with increased risk of enteric infections, bone fractures, and vitamin B12 deficiency. Counsel patients on risks and benefits.
* For oral suspension, shake well before use.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and/or a qualified healthcare provider for any questions regarding drug therapy. Dosing may vary based on individual patient factors, local protocols, and specific product formulations.*
